Abstract
Aim: The aim of the current study was to investigate whether FCGR polymorphisms are associated with responsiveness to anti-TNF-α therapy in patients with spondyloarthropathy, psoriasis, and Crohn's disease. Materials & methods: We conducted a meta-analysis to evaluate the association between the functional FCGR3A F158V and FCGR2A R131H polymorphisms and responsiveness to TNF blockers. Results: The meta-analysis indicated that responsiveness to TNF blockers was associated with the FCGR3A V allele (odds ratio: 3.308; 95% CI: 1.053-10.39; p = 0.040) and the FCGR2A RR + RH genotype (odds ratio: 3.904; p = 0.027) in patients with a follow-up time of ≥6 months. Conclusion: FCGR3A V and FCGR2A R allele carriers show better responsiveness to anti-TNF-α therapy in patients with follow-up times ≥6 months.
| Original language | English |
|---|---|
| Pages (from-to) | 1465-1477 |
| Number of pages | 13 |
| Journal | Pharmacogenomics |
| Volume | 17 |
| Issue number | 13 |
| DOIs | |
| Publication status | Published - 2016 Aug |
Bibliographical note
Publisher Copyright:© 2016 Future Medicine Ltd.
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
Keywords
- FCGR polymorphism
- TNF blockers
- responsiveness
- spondyloarthropathy
ASJC Scopus subject areas
- Molecular Medicine
- Genetics
- Pharmacology